Search

Your search keyword '"Seetharamu, Nagashree"' showing total 286 results
Start Over Author "Seetharamu, Nagashree"
286 results on '"Seetharamu, Nagashree"'

1. The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases

Author

Lee, Chung-Shien, Seetharamu, Nagashree, Rezaei, Nima, Series Editor, Ahmed, Atif A., Editorial Board Member, Aguiar, Rodrigo, Editorial Board Member, Ambrosio, Maria R., Editorial Board Member, Artac, Mehmet, Editorial Board Member, Augustine, Tanya N., Editorial Board Member, Bambauer, Rolf, Editorial Board Member, Bhat, Ajaz Ahmad, Editorial Board Member, Bertolaccini, Luca, Editorial Board Member, Bianchini, Chiara, Editorial Board Member, Cavic, Milena, Editorial Board Member, Chakrabarti, Sakti, Editorial Board Member, Cho, William C. S., Editorial Board Member, Czarnecka, Anna M., Editorial Board Member, Domingues, Cátia, Editorial Board Member, Eşkazan, A. Emre, Editorial Board Member, Fares, Jawad, Editorial Board Member, Fonseca Alves, Carlos E., Editorial Board Member, Fru, Pascaline, Editorial Board Member, Da Gama Duarte, Jessica, Editorial Board Member, García, Mónica C., Editorial Board Member, Gener, Melissa A.H., Editorial Board Member, Estrada Guadarrama, José Antonio, Editorial Board Member, Hargadon, Kristian M., Editorial Board Member, Holvoet, Paul, Editorial Board Member, Jurisic, Vladimir, Editorial Board Member, Kabir, Yearul, Editorial Board Member, Katsila, Theodora, Editorial Board Member, Kleeff, Jorg, Editorial Board Member, Liang, Chao, Editorial Board Member, Tan, Mei Lan, Editorial Board Member, Li, Weijie, Editorial Board Member, Prado López, Sonia, Editorial Board Member, Macha, Muzafar A., Editorial Board Member, Malara, Natalia, Editorial Board Member, Orhan, Adile, Editorial Board Member, Prado-Garcia, Heriberto, Editorial Board Member, Pérez-Velázquez, Judith, Editorial Board Member, Rashed, Wafaa M., Editorial Board Member, Sanguedolce, Francesca, Editorial Board Member, Sorrentino, Rosalinda, Editorial Board Member, Shubina, Irina Zh., Editorial Board Member, de Araujo, Heloisa Sobreiro Selistre, Editorial Board Member, Torres-Suárez, Ana Isabel, Editorial Board Member, Włodarczyk, Jakub, Editorial Board Member, Yeong, Joe Poh Sheng, Editorial Board Member, Toscano, Marta A., Editorial Board Member, Wong, Tak-Wah, Editorial Board Member, Yin, Jun, Editorial Board Member, and Yu, Bin, Editorial Board Member

Published
2023
Full Text
View/download PDF

2. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Abdel-Karim, Isam, Abdelsalam, Mahmoud, Addeo, Alfredo, Aguado, Carlos, Alexander, Patrick, Alt, Jürgen, Azzi, Georges, Balaraman, Rama, Biesma, Bonne, Blackhall, Fiona, Bohnet, Sabine, Boleti, Ekaterini, Borghaei, Hossein, Bradbury, Penelope, Brighenti, Matteo, Campbell, Nicholas, Campbell, Toby, Canon, Jean-Luc, Cappuzzo, Federico, Costa, Enric Carcereny, Cavanna, Luigi, Cetnar, Jeremy, Chella, Antonio, Chouaid, Christos, Christoph, Daniel, Castán, Javier Cortés, Dakhil, Shaker, de Castro Carpeño, Francisco Javier, de Marinis, Filippo, Delmonte, Angelo, Demedts, Ingel, Demey, Wim, Dits, Joyce, del Pilar Diz Taín, Maria, Gómez, Manuel Dómine, Dorius, Timothy, Dumoulin, Daphne, Duruisseaux, Michaël, Eaton, Keith, González, Emilio Esteban, Evans, Devon, Faehling, Martin, Farrell, Nicholas, Feinstein, Trevor, Font, Enriqueta Felip, Garcia Campelo, Maria Rosario, Garon, Edward, Garrido López, María Pilar, Germonpré, Paul, Gersten, Todd, Cao, Maria Gonzalez, Gopaluni, Srivalli, Greillier, Laurent, Grossi, Francesco, Guisier, Florian, Gurubhagavatula, Sarada, Calderón, Vanesa Gutiérrez, Hakimian, David, Hall, Richard, Jr., Hao, Desirée, Harris, Ronald, Hashemi, Sayed, He, Kai, Hendriks, Lizza, Huang, Chao, Ibrahim, Emad, Jain, Sharad, Johnson, Melissa, Jones, Benjamin, Jones, Monte, Juan Vidal, Óscar José, Juergens, Rosalyn, Kaderbhai, Courèche, Kastelijn, Elisabeth A (Lisanne), Keresztes, Roger, Kio, Ebenezer, Kokowski, Konrad, Konduri, Kartik, Kulkarni, Swati, Kuon, Jonas, Kurkjian, Carla, Labbé, Catherine, Lerner, Rachel, Lim, Farah, Madroszyk-Flandin, Anne, Marathe, Omkar, Martincic, Danko, McClay, Edward, McIntyre, Kristi, Mekhail, Tarek, Misino, Andrea, Molinier, Olivier, Morabito, Alessandro, Morócz, Éva, Müller, Veronika, Nagy, Tünde, Nguyen, Anthony V., Nidhiry, Emmanuel, Okazaki, Ian, Ortega-Granados, Ana Laura, Ostoros, Gyula, Oubre, David, Owen, Scott, Pachipala, Krishna, Park, David, Patel, Pareshkumar, Percent, Ivor, Pérol, Maurice, Peters, Solange, Piet, Berber, Planchard, David, Polychronis, Andreas, Aix, Santiago Ponce, Pons-Tostivint, Elvire, Popat, Sanjaykumar, Pulla, Mariano Provencio, Quantin, Xavier, Quéré, Gilles, Rafique, Noman, Ramaekers, Ryan, Reck, Martin, Reiman, Anthony, Reinmuth, Niels, Reynolds, Craig, Rodríguez-Abreu, Delvys, Romano, Gianpiero, Roque, Tammy, Salzberg, Matthew, Sanborn, Rachel, Sandiego, Sergio, Schaefer, Eric, Schreeder, Marshall, Seetharamu, Nagashree, Seneviratne, Lasika, Shah, Purvi, Shunyakov, Leonid, Slater, Dennis, Parra, Hector Soto, Stigt, Johannes, Stilwill, Joseph, Su, Jingdong, Surmont, Veerle, Swink, Alicia, Szalai, Zsuzsanna, Talbot, Toby, Garcia, Alvaro Taus, Theelen, Willemijn, Thompson, Jonathan, Tiseo, Marcello, Uprety, Dipesh, Uyeki, James, van der Leest, Kornelius Cor, Van Ho, Anthony, van Putten, John, Estévez, Sergio Vázquez, Veatch, Andrea, Vergnenègre, Alain, Ward, Patrick, Weise, Amy, Weiss, Matthias, Whitehurst, Matthew, Zai, Silvia, Zalcman, Gérard, Zuniga, Richard, Borghaei, H., de Marinis, F., Dumoulin, D., Reynolds, C., Theelen, W.S.M.E., Percent, I., Gutierrez Calderon, V., Johnson, M.L., Madroszyk-Flandin, A., Garon, E.B., He, K., Planchard, D., Reck, M., Popat, S., Herbst, R.S., Leal, T.A., Shazer, R.L., Yan, X., Harrigan, R., and Peters, S.

Published
2024
Full Text
View/download PDF

9. Contributors

Author

Ahmed, Ebtesam, primary, Akpunonu, Basil E., additional, Alam, Amit, additional, Bain, Kara E., additional, Beizer, Judith L., additional, Bernstein, David, additional, Cacace, Frank, additional, Chacra, Wadih, additional, Cheng, Kwan, additional, Crannage, Andrew J., additional, Dawkins, Makeda, additional, Ehrlich, Jason, additional, Ginzburg, Lev, additional, Hirsch, Bruce E., additional, Ho, Christopher W., additional, Hughes, Gregory J., additional, Hummell, Jeannine, additional, Iakovou, Annamaria, additional, Jones, Shannon, additional, Kaplan, Michael, additional, Kassel, Lynn Eileen, additional, Katona, Kyle C., additional, Khanijo, Sameer, additional, Khanin, Yuriy, additional, Lam, Alan S., additional, Lee, Chung-Shien, additional, Lee, Susan MK, additional, Lichtman, Devora, additional, Martin, Michelle T., additional, Means, Kimberly, additional, Moore, Samantha, additional, Murphy, Julie A., additional, Myers, Alyson K., additional, Ng, Kimberly E., additional, Paralkar, Neha, additional, Pitlick, Jamie M., additional, Presswala, Lubaina S., additional, Putterman, Daniel, additional, Qiu, Shuhao, additional, Rahyab, Ali Seyar, additional, Rand, Joel Eugene, additional, Rickard, Joshua P., additional, Ruan, Jonathan S., additional, Saad, Maria Sedky, additional, Safi, Fadi, additional, Seetharamu, Nagashree, additional, Shafeeq, Hira, additional, Souffrant, Marcel, additional, Tran, Tran H., additional, Din, Shahab Ud, additional, and Van Hise, Nicholas W., additional

Published
2022
Full Text
View/download PDF

17. 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)

Author

Fisher, Terrence, primary, Evans, Elizabeth, additional, Mallow, Crystal, additional, Foster, Amber, additional, Leonard, John, additional, Chaney, Marya, additional, Mekhail, Tarek, additional, Seetharamu, Nagashree, additional, Steuer, Conor, additional, Saba, Nabil F, additional, Adkins, Douglas, additional, Thaddeus Beck, J, additional, Algazi, Alain, additional, Burtness, Barbara, additional, Baumgart, Megan, additional, Hager, Steven, additional, Chay, Christopher, additional, Spira, Alexander, additional, and Zauderer, Maurice, additional

Published
2023
Full Text
View/download PDF

19. Clinical predictors of premature radiotherapy terminations in senior adults with oral cavity and laryngeal carcinoma.

Author

Cooper, Dylan J., Travaglia, Isabella, Guller, Meytal, Talcott, Wesley J., Ghaly, Maged, Miles, Brett A., Frank, Douglas, Seetharamu, Nagashree, and Parashar, Bhupesh

Subjects
LOGISTIC regression analysis, LARYNGEAL cancer, RADIOTHERAPY, REGRESSION analysis, SURVIVAL rate
Abstract

Introduction: The underlying factors that contribute to early radiotherapy (RT) termination are understudied, especially in the era of hypofractionated treatment regimens. In this retrospective investigation, we examined the characteristics and causes of premature RT terminations in senior adults (>70 years old) with oral cavity (OC) and laryngeal carcinomas. Methods: Hundred and eighty‐eight patients treated with RT ± systemic therapy for OC and laryngeal cancer from 2017 to 2022 were identified. Premature termination was defined as completion of less than 95% of the prescribed RT. Logistic regression analysis was performed to examine factors predictive of premature termination, and survival was determined using the Kaplan–Meier method. Results: Twenty patients (10.6%) experienced premature RT terminations. On regression analysis, ECOG score at initiation of RT was the only covariate studied to be independently associated with premature termination (OR 2.00, 95%CI: [1.21, 3.30], p = 0.007). Three‐year overall survival (49.1% vs. 77.3%) was significantly reduced in the termination cohort (p < 0.0001). Conclusions: This analysis demonstrated over 1 in 10 patients had premature RT termination, which prognosticated inferior survival outcomes. Poor performance status may highlight patients at risk for premature termination and thus identify good candidates for hypofractionated protocols. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Author

Borghaei, H., primary, de Marinis, F., additional, Dumoulin, D., additional, Reynolds, C., additional, Theelen, W.S.M.E., additional, Percent, I., additional, Gutierrez Calderon, V., additional, Johnson, M.L., additional, Madroszyk-Flandin, A., additional, Garon, E.B., additional, He, K., additional, Planchard, D., additional, Reck, M., additional, Popat, S., additional, Herbst, R.S., additional, Leal, T.A., additional, Shazer, R.L., additional, Yan, X., additional, Harrigan, R., additional, Peters, S., additional, Abdel-Karim, Isam, additional, Abdelsalam, Mahmoud, additional, Addeo, Alfredo, additional, Aguado, Carlos, additional, Alexander, Patrick, additional, Alt, Jürgen, additional, Azzi, Georges, additional, Balaraman, Rama, additional, Biesma, Bonne, additional, Blackhall, Fiona, additional, Bohnet, Sabine, additional, Boleti, Ekaterini, additional, Borghaei, Hossein, additional, Bradbury, Penelope, additional, Brighenti, Matteo, additional, Campbell, Nicholas, additional, Campbell, Toby, additional, Canon, Jean-Luc, additional, Cappuzzo, Federico, additional, Costa, Enric Carcereny, additional, Cavanna, Luigi, additional, Cetnar, Jeremy, additional, Chella, Antonio, additional, Chouaid, Christos, additional, Christoph, Daniel, additional, Castán, Javier Cortés, additional, Dakhil, Shaker, additional, de Castro Carpeño, Francisco Javier, additional, de Marinis, Filippo, additional, Delmonte, Angelo, additional, Demedts, Ingel, additional, Demey, Wim, additional, Dits, Joyce, additional, del Pilar Diz Taín, Maria, additional, Gómez, Manuel Dómine, additional, Dorius, Timothy, additional, Dumoulin, Daphne, additional, Duruisseaux, Michaël, additional, Eaton, Keith, additional, González, Emilio Esteban, additional, Evans, Devon, additional, Faehling, Martin, additional, Farrell, Nicholas, additional, Feinstein, Trevor, additional, Font, Enriqueta Felip, additional, Garcia Campelo, Maria Rosario, additional, Garon, Edward, additional, Garrido López, María Pilar, additional, Germonpré, Paul, additional, Gersten, Todd, additional, Cao, Maria Gonzalez, additional, Gopaluni, Srivalli, additional, Greillier, Laurent, additional, Grossi, Francesco, additional, Guisier, Florian, additional, Gurubhagavatula, Sarada, additional, Calderón, Vanesa Gutiérrez, additional, Hakimian, David, additional, Hall, Richard, additional, Hao, Desirée, additional, Harris, Ronald, additional, Hashemi, Sayed, additional, He, Kai, additional, Hendriks, Lizza, additional, Huang, Chao, additional, Ibrahim, Emad, additional, Jain, Sharad, additional, Johnson, Melissa, additional, Jones, Benjamin, additional, Jones, Monte, additional, Juan Vidal, Óscar José, additional, Juergens, Rosalyn, additional, Kaderbhai, Courèche, additional, Kastelijn, Elisabeth A (Lisanne), additional, Keresztes, Roger, additional, Kio, Ebenezer, additional, Kokowski, Konrad, additional, Konduri, Kartik, additional, Kulkarni, Swati, additional, Kuon, Jonas, additional, Kurkjian, Carla, additional, Labbé, Catherine, additional, Lerner, Rachel, additional, Lim, Farah, additional, Madroszyk-Flandin, Anne, additional, Marathe, Omkar, additional, Martincic, Danko, additional, McClay, Edward, additional, McIntyre, Kristi, additional, Mekhail, Tarek, additional, Misino, Andrea, additional, Molinier, Olivier, additional, Morabito, Alessandro, additional, Morócz, Éva, additional, Müller, Veronika, additional, Nagy, Tünde, additional, Nguyen, Anthony V., additional, Nidhiry, Emmanuel, additional, Okazaki, Ian, additional, Ortega-Granados, Ana Laura, additional, Ostoros, Gyula, additional, Oubre, David, additional, Owen, Scott, additional, Pachipala, Krishna, additional, Park, David, additional, Patel, Pareshkumar, additional, Percent, Ivor, additional, Pérol, Maurice, additional, Peters, Solange, additional, Piet, Berber, additional, Planchard, David, additional, Polychronis, Andreas, additional, Aix, Santiago Ponce, additional, Pons-Tostivint, Elvire, additional, Popat, Sanjaykumar, additional, Pulla, Mariano Provencio, additional, Quantin, Xavier, additional, Quéré, Gilles, additional, Rafique, Noman, additional, Ramaekers, Ryan, additional, Reck, Martin, additional, Reiman, Anthony, additional, Reinmuth, Niels, additional, Reynolds, Craig, additional, Rodríguez-Abreu, Delvys, additional, Romano, Gianpiero, additional, Roque, Tammy, additional, Salzberg, Matthew, additional, Sanborn, Rachel, additional, Sandiego, Sergio, additional, Schaefer, Eric, additional, Schreeder, Marshall, additional, Seetharamu, Nagashree, additional, Seneviratne, Lasika, additional, Shah, Purvi, additional, Shunyakov, Leonid, additional, Slater, Dennis, additional, Parra, Hector Soto, additional, Stigt, Johannes, additional, Stilwill, Joseph, additional, Su, Jingdong, additional, Surmont, Veerle, additional, Swink, Alicia, additional, Szalai, Zsuzsanna, additional, Talbot, Toby, additional, Garcia, Alvaro Taus, additional, Theelen, Willemijn, additional, Thompson, Jonathan, additional, Tiseo, Marcello, additional, Uprety, Dipesh, additional, Uyeki, James, additional, van der Leest, Kornelius Cor, additional, Van Ho, Anthony, additional, van Putten, John, additional, Estévez, Sergio Vázquez, additional, Veatch, Andrea, additional, Vergnenègre, Alain, additional, Ward, Patrick, additional, Weise, Amy, additional, Weiss, Matthias, additional, Whitehurst, Matthew, additional, Zai, Silvia, additional, Zalcman, Gérard, additional, and Zuniga, Richard, additional

Published
2023
Full Text
View/download PDF

23. Efficacy of ketamine mouthwash in the management of oral and pharyngeal toxicity associated with head and neck chemoradiotherapy: protocol for a phase II, Simon’s two-stage trial

Author

Koffler, Daniel, primary, Eckstein, Jacob, additional, Herman, Joseph, additional, Martins-Welch, Diana, additional, Seetharamu, Nagashree, additional, Ghaly, Maged, additional, Kohn, Nina, additional, Potters, Louis, additional, Frank, Douglas, additional, Sullivan, Kevin, additional, and Parashar, Bhupesh, additional

Published
2023
Full Text
View/download PDF

24. Figure S4 from A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer

Author

Shafique, Michael R., primary, Fisher, Terrence L., primary, Evans, Elizabeth E., primary, Leonard, John E., primary, Pastore, Desa Rae E., primary, Mallow, Crystal L., primary, Smith, Ernest, primary, Mishra, Vikas, primary, Schröder, Andreas, primary, Chin, Kevin M., primary, Beck, Joseph T., primary, Baumgart, Megan A., primary, Govindan, Ramaswamy, primary, Gabrail, Nashat Y., primary, Spira, Alexander I., primary, Seetharamu, Nagashree, primary, Lou, Yanyan, primary, Mansfield, Aaron S., primary, Sanborn, Rachel E., primary, Goldman, Jonathan W., primary, and Zauderer, Maurice, primary

Published
2023
Full Text
View/download PDF

26. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

Author

Jimeno, Antonio, Bauman, Julie E., Weissman, Charles, Adkins, Douglas, Schnadig, Ian, Beauregard, Patrice, Bowles, Daniel W., Spira, Alexander, Levy, Benjamin, Seetharamu, Nagashree, Hausman, Diana, Walker, Luke, Rudin, Charles M., and Shirai, Keisuke

Published
2015
Full Text
View/download PDF

31. Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84).

Author

Fisher, Terrence Lee, primary, Evans, Elizabeth E., additional, Mallow, Crystal L., additional, Foster, Amber, additional, Boise, Megan, additional, Smith, Ernest, additional, Leonard, John E., additional, Chaney, Marya F., additional, Beck, Joseph Thaddeus, additional, Hager, Steven Jeffrey, additional, Mekhail, Tarek, additional, Seetharamu, Nagashree, additional, Baumgart, Megan, additional, Saba, Nabil F., additional, Steuer, Conor Ernst, additional, Adkins, Douglas, additional, Burtness, Barbara, additional, and Zauderer, Maurice, additional

Published
2022
Full Text
View/download PDF

36. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment

Author

Shonka, David C., primary, Ho, Alan, additional, Chintakuntlawar, Ashish V., additional, Geiger, Jessica L., additional, Park, Jong C., additional, Seetharamu, Nagashree, additional, Jasim, Sina, additional, Abdelhamid Ahmed, Amr H., additional, Bible, Keith C., additional, Brose, Marcia S., additional, Cabanillas, Maria E., additional, Dabekaussen, Kirsten, additional, Davies, Louise, additional, Dias‐Santagata, Dora, additional, Fagin, James A., additional, Faquin, William C., additional, Ghossein, Ronald A., additional, Gopal, Raj K., additional, Miyauchi, Akira, additional, Nikiforov, Yuri E., additional, Ringel, Matthew D., additional, Robinson, Bruce, additional, Ryder, Mabel M., additional, Sherman, Eric J., additional, Sadow, Peter M., additional, Shin, Jennifer J., additional, Stack, Brendan C., additional, Tuttle, R. Michael, additional, Wirth, Lori J., additional, Zafereo, Mark E., additional, and Randolph, Gregory W., additional

Published
2022
Full Text
View/download PDF

38. The Evolving Role of PD-L1 Inhibition in Non-Small Cell Lung Cancer: A Review of Durvalumab and Avelumab

Author

Neumann, Melissa, Murphy, Neal, and Seetharamu, Nagashree

Subjects
Article
Abstract

Non-small cell lung cancer (NSCLC) was traditionally associated with a poor prognosis. Between 2010 and 2016, the 5-years overall survival for all stages combined was about 25 percent. However, the recent use of immunotherapy has led to significant improvements in progression free survival (PFS) and overall survival (OS). Immune check point inhibitors enable the host immune system to mount a lethal response against tumor cells. Both PD-1 (nivolumab, pembrolizumab, cemipilimab) and PD-L1 inhibitors (atezolizumab and durvalumab) have been approved by the FDA for use in NSCLC, either as individual agents or in combination with platinum-based chemotherapy, radiation therapy, or other agents. As the future of immunotherapy for lung cancer continues to evolve, with multiple agents approved or in various stages of clinical research, it is imperative that we understand the mechanism of action, clinical activity, ongoing clinical trials, indications for use and toxicity for individual agents in addition to having general, basic knowledge about this new class of cancer therapeutics. In this review, we focus on two of the newer PD-L1 inhibitors, durvalumab and avelumab.

Published
2021

41. Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform

Author

Martin, Richard L., primary, Grant, Michael J., additional, Kimani, Stephen, additional, Midha, Shonali, additional, May, Jori, additional, Patell, Rushad, additional, Collier, Emily, additional, Furfaro, David, additional, Bodine, Charles, additional, Reap, Leo, additional, Shah, Nikesh, additional, DeLaune, Jess, additional, Brusca, Samuel, additional, Olazagasti, Coral, additional, Goyal, Shreya, additional, Rubinstein, Samuel, additional, Hakim, Nausheen, additional, Qin, Shuai, additional, Browning, Sabrina L., additional, Sena, Laura, additional, Gilbert, Jill, additional, Davidson, Mario, additional, Lovly, Christine M., additional, Seetharamu, Nagashree, additional, Rangachari, Deepa, additional, Murphy, Martina, additional, Chatwal, Monica, additional, Paschal, Rita, additional, Henry, Elizabeth, additional, Collichio, Frances, additional, and Green, Jennifer R., additional

Published
2022
Full Text
View/download PDF

42. Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data

Author

Lee,Chung-Shien, Milone,Matthew, and Seetharamu,Nagashree

Subjects
OncoTargets and Therapy, respiratory tract diseases
Abstract

Chung-Shien Lee,1,2 Matthew Milone,3 Nagashree Seetharamu2 1Department of Clinical Health Professions, St. John’s University, Queens, NY, USA; 2Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Lake Success, NY, USA; 3Pharmacy Department, Long Island Jewish Medical Center, New Hyde Park, NY, USACorrespondence: Nagashree Seetharamu Email nseetharamu@northwell.eduAbstract: The use of epidermal growth factor receptor (EGFR) inhibitors such as osimertinib has improved outcomes and quality of life for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Osimertinib has become the preferred EGFR tyrosine kinase inhibitor (TKIs) for patients with these mutations after demonstrating superior efficacy compared to first generation EGFR TKIs, such as erlotinib and gefitinib. More recently osimertinib has also shown to be beneficial in patients with resectable NSCLC harboring EGFR mutations irrespective of whether they received adjuvant chemotherapy or not. The drug is now FDA approved in this setting. With osimertinib being used more commonly in earlier stage and front-line settings, we are more likely to see patients who develop resistance to this drug. The aim of this review is to provide a comprehensive review of the data with osimertinib in EGFR mutation positive NSCLC, potential resistance mechanisms and an overview of key ongoing clinical trials.Keywords: non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitor, osimertinib

Published
2021

44. Osteoradionecrosis versus Cancer Recurrence: An Unresolved Clinical Dilemma.

Author

Tufano-Sugarman, Andrea M., Wang, Kevin Y., Kohn, Nina, Ghaly, Maged, Parashar, Bhupesh, Frank, Douglas, Kamdar, Dev, Pereira, Lucio, Fantasia, John, and Seetharamu, Nagashree

Subjects
CANCER relapse, HEAD & neck cancer, OSTEORADIONECROSIS, POSITRON emission tomography, SQUAMOUS cell carcinoma, SYMPTOMS, COMPUTED tomography
Abstract

Introduction: Osteoradionecrosis is a rare and debilitating risk of definitive chemoradiotherapy for head and neck squamous cell carcinoma. It is difficult to distinguish between osteoradionecrosis and recurrent or progressive disease, as clinical and radiologic features may be similar. Our aim was to compare the clinical presentation and radiologic features of osteonecrosis with those of recurrent or progressive cancer. Methods: We conducted a single-center case series of 19 patients with head and neck squamous cell carcinoma diagnosed between 2011 and 2019 who subsequently developed clinical and/or radiological suspicion of osteoradionecrosis. The population was a referred sample from head and neck cancer physicians at Northwell Health Cancer Institute. Clinician notes and imaging reports were reviewed to assign a final diagnosis of either cancer, osteonecrosis, or indeterminate. Results: No differences were found in the clinical presentation or radiologic features between groups. Median time between treatment and development of symptoms was longer in patients with a final diagnosis of osteoradionecrosis than recurrent or progressive disease (5 vs. 3 months), but this difference was not statistically significant. Radiation dose and type were not associated with diagnosis. Mean standard uptake value maximums on positron emission tomography/computed tomography were significantly higher in the cancer group (median 14.8 vs. 9.1, p < 0.0152). At 1 year after first suspicion of osteoradionecrosis, 100% of osteoradionecrosis patients were alive, versus 28.6% of cancer patients. Discussion/Conclusion: There is significant overlap in clinical and radiologic features of osteoradionecrosis and cancer. Standard uptake maximums may be helpful in predicting diagnosis. Occurrence of symptoms within 6 months of completing chemoradiotherapy should raise the concern for malignancy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results